Zolafren tablets are shown for:

• treatment of schizophrenia;
• maintenance of the reached clinical effect at long therapy at patients at whom it was observed the response to initial therapy;
• treatment of maniacal episodes of moderate and heavy degree;
• prevention of repeated attacks at patients with bipolar disorders in which affirmative answer at treatment was received by mania olanzapine.

Structure

Active ingredient: 1 tablet contains 5 mg or 10 mg of olanzapine;

Excipients: lactose, cellulose microcrystalline, starch sodium (type A), magnesium stearate;

Cover: gipromelloz (gipromelloz), polyethyleneglycol (Makrogol) 400, Yellow No. 6 Al-Lake dye (E 110), titan dioxide (E 171), ferrous oxide yellow (E172), lactose.

Contraindication

Hypersensitivity to active ingredient or to auxiliary components of drug.

Known risk of closed-angle glaucoma.

Route of administration

Treatment of schizophrenia, maniacal episodes and prevention of a recurrence of bipolar disorder. To define a daily dose on the basis of the clinical status in the range from 5 to 20 mg a day. To carry out increase in the recommended initial dose with intervals not less than 24 hours only after clinical inspection. To apply olanzapine irrespective of meal as meal does not influence medicament absorption. At medicament withdrawal of completion of therapy it is necessary to carry out gradually.

Feature of use

Pregnant

Olanzapine during pregnancy needs to be applied only when the expected results justify potential risk for a fruit.

by

for treatment of children and teenagers.

Drivers

With care, are possible dizziness and drowsiness.

Overdose

Symptoms. Very often (> 10%): tachycardia, agitation/aggression, a dysarthtia, various extrapyramidal symptoms and reduced level of consciousness, varies from a sedation to a coma.

Other considerable complications of overdose. The lethal outcome was noted at acute overdose at the level of 450 mg, but there were also survival cases after acute overdose after reception of 2 g of olanzapine orally.

Treatment. There is no specific antidote. The medicaments causing vomiting are not recommended. It is recommended standard procedures at overdose (for example gastric lavage, intake of activated carbon). It was revealed that the concomitant use of activated carbon reduces bioavailability of olanzapine at oral administration by 50-60%.

Side effects

Most frequent side reactions (were observed at ≥ 1% of patients) connected with use of olanzapine during clinical trials were such: drowsiness, increase in body weight, an eosinophilia, increase in level of prolactin, cholesterol, glucose and triglycerides in blood, a glucosuria, increase in appetite, dizziness, an akathisia, parkinsonism, a leukopenia, a neutropenia, dyskinesia, orthostatic hypotension, anticholinergic effects, tranzitorny symptomless increase in hepatic transaminases, rash, an asthenia, increased fatigue, a hyperthermia, an arthralgia, increase in level of an alkalinfosfataza, gammaglutamiltransferaza, uric acid, KFK and hypostases.

Interaction

with care olanzapine with other medicaments with the known risk of increase in an interval of QTs.

to Store

at a temperature not above 25 °C, in original packing.

to Store

out of children's reach.

Expiration date - 3 years.